anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Androgen ablation is the mainstay of treatment for advanced prostate cancer. However,luteinizing hormone-releasing (LHRH) agonists are associated with accelerated bone loss, osteoporosis and fractures. An alternative is the non steroidal antiandrogen, bicalutamide, which acts at the androgen receptor and maintains serum testosterone levels. Our aim was to assess the effects of these two treatments on bone mineral density (BMD) of selected groups of patients, based on their BMD at presentation. All patients will undergo peripheral bone densitometry of the forearm, using dual energy X-ray absorptiometry. Osteoporotic patients, at high risk of fractures, will be commenced on bicalutamide. Osteopenic and normal BMD patients will be commenced on LHRH agonists. All osteopenic and osteoporotic patients will be given calcium and vitamin D supplementation.Patients will undergo annual bone densitometry scans, and will be seen in the clinic every 3 months to monitor well-being and PSA levels. Any patient who fails to respond or escapes treatment with hormone monotherapy will be managed according to the clinical situation by either being switched to a combination of LHRH and bicalutamide or additional oestrogen therapy.
DSP107 will be administered by intravenous infusion over 1 hour on Days 1, 8 and 15 of each 21-day cycle for up to 12 treatment cycles. Starting dose will be 0.01 mg/kg and maximum dose will not exceed 10 mg/kg.
In the control group, information about physical activity will be given without applying the physical activity program. Control group's assessments will be performed when they are included in the study, at the end of 12 weeks and 24 weeks.
The present invention provides an anti-CD 30 antibody. In particular, the invention provides a class of monoclonal antibodies targeting CD 30. The invention provides a group of anti-CD 30 antibodies obtained by hybridoma technology, and also provides humanized anti-CD 30 antibodies. The anti-CD 30 antibodies of the invention are capable of specifically binding CD30 and have high affinity. Thus, the antibodies of the invention have promise for the treatment of CD 30-related diseases, particularly lymphomas. On this basis, the present invention has been completed.
Articaine/epinephrine and lidocaine/epinephrine are the most common routine local anesthetic agents currently used in dentistry. However, their anesthetic efficacy and pain control in patients with symptomatic irreversible pulpitis via inferior alveolar nerve block is very low. The aim of this study is to investigate the efficacy of clonidine versus articaine/epinpephrine as a local anesthetic agent for a buccal infiltration after IANB administration with lidocaine for (1) successful IANB, (2) hemodynamic stability, and (3) reducing dental anxiety for endodontic treatment in mandibular molars diagnosed with symptomatic irreversible pulpitis. 100 patients with first or second mandibular molars diagnosed with symptomatic irreversible pulpitis will be enrolled. Patients will randomly receive either 1.7mL of clonidine (1:100,000) or 1.7mL of 4% articaine with epinephrine (1:100,000) using buccal infiltration technique after administration of 1.7mL of 2% lidocaine with epinephrine (1:100,000) using an IANB technique. 15 minutes after injection, lip numbness will be checked. Those who reported lip numbness will be checked for pulpal anesthesia. Those who achieve profound pulpal anesthesia will be included in the study. Patient's pain score will be recorded using a Heft-Parker visual analog scale before, during and after endodontic treatment. Success in IANB is defined as no or mild pain upon endodontic access cavity preparation and initial canal instrumentation. The hemodynamic parameters and pain management will be measured before and after root canal treatment with specific intervals. Patient's dental anxiety level will be measured by VAS-Anxiety preoperatively, before IANB administration, before endodontic treatment and after the treatment.
The present invention belongs to the technical field of biological medicines. Disclosed is a novel ceramide which has a structure represented as formula I. Further disclosed in the present invention are a preparation method for and the use of the ceramide. The present invention uses naturally-sourced and readily-available 10-hydroxycarboxylic acid as a starting raw material to construct the ceramide having a novel structure. The preparation method has a simple and convenient synthetic route and is suitable for large-scale production. Meanwhile, the obtained ceramide shows more excellent effects in the aspects of tissue repair, anti-inflammatory repair, tissue healing, moisturizing and anti-aging, and thus can be used in the fields of health care products, cosmetics and drugs.
Idiopathic membranous nephropathy is most common cause of glomerulonephritis in adults. Persistent high grade proteinuria or progressively decrease of renal function is a risk factor for end stage renal disease in idiopathic membranous nephropathy. It has been reported that cyclosporin in patients with idiopathic membranous nephropathy decreases proteinuria and improve renal function. Mycophenolate mofetil is a recently developed immunosuppressive agent with fewer side effect than cyclosporin. In this study patients with high risk group of progressive idiopathic membranous nephropathy will be treated with mycophenolate mofetil and low dose prednisone. The outcome will be compared to controls treated with cyclosporin and low dose prednisone.
The invention discloses a method and a system for evaluating the risk of a hypotensive event in dialysis. The first derivative curve of the ideal RBV curve is determined. And collecting RBV data in the dialysis process at preset interval duration, filtering the collected data each time by using a Kalman filter, calculating the descent rate of the RBV data, and filtering the descent rate by using the Kalman filter. And calculating a safety line and a forbidden line at the current moment through the first-order derivative curve, and determining the risk coefficient according to the comparison of the reduction rate and the sizes of the safety line and the forbidden line. The invention can filter the interference in the collected RBV data and improve the accuracy of evaluating the risk of the hypotensive event in the dialysis process of the patient by using the RBV. At the same time, the dynamic threshold value is used for calculating the risk of hypotension events, so that the dynamic threshold value can better adapt to the tolerance change of the patient to the unbalance degree in different time periods. The filtering algorithm is simple, the processing speed is high, and real-time processing of RBV data can be realized.
On November 8, 1923, William John Adie described an unusual disorder to the Section of Neurology of the Royal Society of Medicine. The condition comprised frequent momentary stereotyped impairments of consciousness that occurred in children, did not respond to antiseizure medications, and did not develop into epilepsy, as that term was then commonly understood, since no convulsive seizures occurred. After some time, the episodes terminated spontaneously, leaving the sufferer unhandicapped and neurologically intact. Almost certainly, Adie had described the present-day entity of childhood absence epilepsy. He termed it "pyknolepsy," knowing that the name "pyknolepsie" had been used for a similar disorder in Germany from 1916 onwards, though not reported elsewhere. Following Adie's account, published in 1924, reports of the disorder appeared in the English and French-language literature and continued to be published in German. It became increasingly accepted that pyknolepsy was a form of epilepsy that was part of Lennox's petit mal triad. The word pyknolepsy itself never became widely used and is now largely forgotten. Adie never took up the topic in print again. However, he had awakened English-language readers to one component in a broadening of the concept of what constituted epilepsy.
PURPOSE:To provide a magnetic plaster having uniformly magnetized adhesive surface, by mixing magnetic powder to a plaster containing an antiphlogistic and analgesic agent, thereby facilitating the application of the plaster to the sensible point of the body, and enabling the exhibition of the synergistic effect of the drug and the magnetic force. CONSTITUTION:A plaster containing a drug such as antiphlogistic agent or analgesic agent, etc. is compounded with magnetic powder to keep the powder by the adhesive force of the plaster. The mixture is spread on a cloth or a film, etc. to obtain a plaster having uniformly magnetized adhesive surface. The physical effect of the magnetic power of the magnetic powder and the chemical effect of the drug compounded in the plaster act synergistically to the body.
In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen and progestin drug metabolism. Inducers of CYP3A4 such as St. John’s wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine and rifampin may decrease the plasma concentration of estrogens and progestins, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase the plasma concentration of estrogens and may result in adverse reactions. 

Co-administration of atorvastatin and certain hormonal products containing ethinyl estradiol increase AUC values for ethinyl estradiol approximately 20 percent. Ascorbic acid and acetaminophen may increase the plasma ethinyl estradiol concentration, possibly by inhibition of conjugation.

Combination hormonal products have been shown to significantly decrease the plasma concentration of lamotrigine likely due to induction of lamotrigine glucuronidation. This may reduce seizure control; therefore, dosage adjustments of lamotrigine may be necessary.
A total 62 patients will be recruited in the study. After voluntary consent, all the patients will be randomly divided into Group-A and B through the envelope method of simple random sampling. Patients in Group-A will be receiving VR based motor priming intervention while Group-B patients will be receiving Motor-Relearning Program as conventional therapy. Whereas, both the groups will be given 16 sessions of their respective protocol, comprising of 45 minutes, 4 times/week for the duration of 4 weeks. Pre and post assessment will be performed for each patient on all three quantitative outcome measures i.e. FMA-UE, CAHAI-13, and MoCA. A trial will be terminated, if the patient reported fatigue of \>8 out of 10 on the Visual Analogue Scale, unable to execute movements, reports pain, eye strain, or signs of volitional fatigue in hemiplegic or non-hemiplegic extremities.
In an embodiment, the present disclosure pertains to a method of treating or preventing C. difficile infections. In some embodiments, the method includes administering an anti-toxin to a subject in need thereof. In some embodiments, the anti-toxin includes a designed ankyrin repeat protein (DARPin). In an additional embodiments, the present disclosure pertains to a composition including an anti-toxin for treating or preventing C. difficile infections. In some embodiments, the anti-toxin includes a DARPin. In some embodiments, the anti-toxin is a monomeric or dimeric DARPin for the neutralization of Clostridium difficile toxin B (TcdB).
BACKGROUND: Type 2 diabetes has traditionally been a risk factor for worse prognosis after myocardial infarction (MI), but major advances have been made in its treatment, and the use of secondary preventive measures has intensified. We evaluated the short- and long-term mortality rates of patients with type 2 diabetes after MI and explored the associations between the characteristics of patients with type 2 diabetes and MI mortality.
METHODS: Mortality rates among consecutive MI patients with type 2 diabetes using oral antidiabetic medication (n = 13,152; 40% female; mean age 73.6 years) and MI patients without diabetes (n = 77,669) treated in Finland from 2004 to 2018 were retrospectively studied using a combination of national registries (median follow-up 5.7 years). Differences between groups were balanced with multivariable adjustments and propensity score matching.
RESULTS: Mortality was higher in patients with type 2 diabetes than in the propensity score-matched controls without diabetes at 30 days (12.6% versus 12.0%: p = 0.013), at 1 year (22.4% versus 21.4%; p = 0.001), and at 15 years (83.2% vs. 73.4%; HR 1.20; 95% CI 1.17-1.24; p < 0.0001) after MI. In subgroup analyses, type 2 diabetes was associated with a poorer prognosis across the spectrum of MI patients. The excess mortality risk was attenuated by increasing age but was similar in both sexes. Male sex, age, cardiovascular and noncardiovascular co-morbidities, lack of revascularization, a longer duration of diabetes, and baseline insulin therapy were associated with increased mortality in patients with type 2 diabetes. The one-year prognosis of patients with type 2 diabetes improved during the study period, but the mortality gap compared to patients without diabetes was not altered.
CONCLUSIONS: Type 2 diabetes had a negative impact on both short- and long-term outcome after MI, but effect sizes were relatively small. Patients with longer duration of diabetes or need for insulin therapy are still at particular risk.
PURPOSE:A composition for the oral cavity, containing an extract obtained from a plant of the family Labiatae, e.g. sage or rosemary, as an active constituent, capable of suppressing the inactivation of the extract of pH in an acidic region, and having inhibitory effects on the foul breath and improved antimicrobial action, and usable for dentifrice, mouth wash, etc. CONSTITUTION:A composition for the oral cavity containing 0.005-2% extract obtained from a plant of the family Labiatae, e.g. sage or rosemary, and having a pH retained at 6.6 or below. The above-mentioned extract gives inhibitory effects on the foul breath. When the extract is used with a sodium alkyl sulfate or Lauric acid monoglyceride, the synergistic effects thereof exhibit specific improved antimicrobial action on Fusobacterium nucleatum. The pH kept at 6.6 or below inhibits the inactivation of the above-mentioned extract, and the effects thereof can be sufficiently produced even on storage for a long term.
Technical information about the content of the MyPlan 2.0. intervention:

MyPlan 2.0. was the eHealth intervention that was used in this study. MyPlan 2.0. is a theory- and user-based intervention. Theories used to develop the intervention are the self-regulation theory and the Health Action Approach model. The intervention targets pre- and post-intentional processes to reach behavior change. The intervention consists of five website visits in five weeks (one per week).

During the first website visit, the participants fill in a short PA questionnaire and based on the answers, they receive personal feedback about their behavior (pre-intentional processes). Knowledge is also provided by giving users the chance to fill in an optional quiz about PA and its beneficial effects. Post-intentional processes are targeted during this first visit by asking the participants to make an action plan. Participants are asked what they want to do (e.g. being more active by cycling during leisure time), when (e.g. every Sunday morning), where (e.g. in the streets nearby) and for how long (e.g. 60 minutes). After answering these questions, the participants can identify difficult situations and possible barriers (i.e. coping planning) while pursuing their goals. Dependent on which barriers they select, specific solutions are given and the participants could choose which ones they consider appropriate and want to apply. After this first website visit, the users can indicate how they want to self-monitor their behaviour (e.g. using an agenda).

One week after finishing the first website visit, the participants receive an email to revisit the website. During this second visit, they receive feedback about their behavioural change process and their goals (e.g. did the participant reach his/her goal or not?). Afterwards the participants have the possibility to adapt their action plan (e.g. setting new, more realistic goals). They can reconsider coping plans, based on barriers they experienced while pursuing their goals. Furthermore, participants can optionally read activity tips. Website visits 3, 4 and 5 are respectively activated one week after the previous visit. Again, the participants are reminded by email. These three last visits are identical to the second visit (review of the action and coping plan).
Standard treatment approaches for patients with localized BC includes BCS followed WBI \[1\], which has demonstrated equivalent local control and survival when compared to mastectomy \[2,3\]. Although conventionally fractionated radiotherapy (RT) (50 Gy 2 Gy per fraction) administered in 25 fractions in 5 weeks was historically used, moderate hypofractionation RT trials utilizing shorter treatment times and higher doses per session have resulted in favorable outcomes \[4,5,6\]. In addition, increased local control and reduced toxicity rates observed in moderate hypofractionation RT trials \[5,6\] have resulted in studies evaluating the use of ultrahypofractionated breast RT which further shorten the treatment time. The results of the FAST-Forward RT trial have shown that adjuvant RT using 26 Gy/5.2 Gy per fraction, over 5 fractions administered in 1 week, was not inferior to the standard 40.05 Gy/15 fx/3 weeks for local tumor control and is equally safe in terms of effects on normal tissue \[7\]. Side effects associated with RT can be more pronounced in patients when RT is combined with surgery and/or chemotherapy \[9\]. There are abundant data describing the safety of combining conventionally fractionated RT following chemotherapy. Similarly, there are several trials which have reported outcomes of patients who have received hypofractionated RT, including subsets of patients who also received chemotherapy demonstrating similar acute and late toxicity profiles compared to standard fractionation regimens \[10, 11, 12, 13\]. Although the FAST-Forward trial included patients who received neoadjuvant and adjuvant chemotherapy and estimates of 5-year cumulative incidence of any moderate or marked clinician-assessed normal tissue effects in the breast or chest wall were reported to be similar for 40 Gy 15 fraction hypofractionated vs the 26 Gy 5 fraction ultrahypofractionated RT regimen (26·8% v 28·5%, respectively), the study was not designed to detect differences for those who had received prior chemotherapy compared to those who did not \[7\]. Retrospective subgroup analysis did not identify differences in adverse effects related to prior chemotherapy, however confidence intervals overlapped, and the power for these retrospective subgroup analyses was low \[19\]. Hence, there is limited data evaluating the toxicity of ultrahypofractionated adjuvant breast RT in patients who have received prior chemotherapy. This study is designed to evaluate the acute and late effects on the breast of ultrahypofractionated WBI using the FAST-forward regimen (26 Gy, 5.2 Gy per fraction delivered in 1 week) in patients \> 60 years of age with pathologically or clinically node-negative early-stage BC who undergo BCS and chemotherapy.
<P>PROBLEM TO BE SOLVED: To provide an immunoglobulin G activator which comprises as an effective ingredient raffinose and is effective for restoration from a physiological immunosuppressive state and inhibition of immunosuppression of the livestock in the lactation state.  <P>SOLUTION: The immunoglobulin G activator for livestock in the lactation period comprises raffinose as an effective ingredient. The starter comprises the activator. The combination of raffinose with a live bacterial agent enhances immunosuppression-inhibiting effects. By the utilization of the immunoglobulin G activator, loss of juvenile livestock is prevented and loss in livestock farming can be reduced.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
The present invention relates to a server for managing a taste in food, which enables a user to be aware of taste type information of the user. According to embodiments of the present invention, the server for managing a taste in food comprises: a communication unit for receiving taste type information from a user device; a storage unit for storing the taste type information input through the communication unit; and a control unit which provides taste type information based on taste dimension information stored in the storage unit. The control unit receives a request for taste type information, provides questions about a plurality of taste dimensions, analyzes an input value of the user related to the questions about the plurality of taste dimensions, and provides information on which type corresponds to an analyzed result among a plurality of taste types. Each of the plurality of taste dimensions includes a pair of taste elements opposite to each other. The pair of taste elements are represented as different alphabets. Each of the questions about the plurality of taste dimensions includes a pair of menus corresponding to the pair of taste elements and preference score criteria. The input value of the user includes one menu selected from among the pair of menus and a score value selected from among the preference score criteria. The taste type information may be output as an alphabet of a corresponding taste element of the pair of taste elements for each of the plurality of taste dimensions.
BACKGROUND: From year to year, the proportion of people living with overweight and obesity in China rises, along with the prevalence of diseases linked to obesity. Although bariatric surgery is gaining popularity, there are still several issues with its promotion compared to Western nations. Since less developed places in China are more widespread due to disparities in the development of different regions, there has been little exploration of the factors that might be related to acceptance of bariatric surgery in these regions.
METHODS: Patients who visited the Department of Gastrointestinal Surgery at the North Sichuan Medical College Affiliated Hospital from 2018 to 2022 and had obesity or other relevant metabolic problems were surveyed using a questionnaire. The relationship between demographic factors, socioeconomic status, and acceptance of bariatric surgery was analyzed.
RESULTS: Of 334 patients, 171 had bariatric surgery. BMI, education level, marriage history, medical insurance, family support, and a history of type 2 diabetes were all linked to having bariatric surgery, according to a univariate analysis. In a multivariate analysis, BMI (P = 0.02), education (P = 0.02), family support (P<0.001), medical insurance coverage (P<0.001), and history of type 2 diabetes (P = 0.004) were all positively associated with a willingness to have bariatric surgery. Among 163 non-bariatric patients with obesity, 15.3% were not opposed to surgery but preferred trying medication first, 54.6% leaned towards medical therapy, and 30% were hesitant. Additionally, a majority of patients (48.55%) often lacked adequate knowledge about weight reduction therapy. Age, height, gender, smoking, drinking, family history of type 2 diabetes, education, and marital status did not significantly differ (P > 0.05).
CONCLUSIONS: Many patients are concerned about the safety of surgical treatment and the possibility of regaining weight. Due to the relatively high cost of bariatric surgery, they tend to choose medical treatment. To enhance the acceptance of bariatric surgery in underdeveloped regions of China, it is crucial to focus on disseminating knowledge about bariatric surgery, offer pertinent health education to the community, and foster support from patients' families. The government should pay more attention to obesity and provide support in the form of medical insurance.